Beam Therapeutics (BEAM) president’s 11,810-share sale covers RSU taxes

Rhea-AI Filing Summary

Beam Therapeutics President Giuseppe Ciaramella reported an automatic sale of 11,810 shares of common stock at $24.58 per share. The shares were sold to cover tax withholding obligations tied to previously granted restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, he directly holds 218,406 shares of Beam Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 11,810 shares ($290,290)

Net Sell 1 txn

Insider Ciaramella Giuseppe

Role President

Sold 11,810 shs ($290K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,810	$24.58	$290K

Holdings After Transaction: Common Stock — 218,406 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,810 shares Sale price: $24.58 per share Shares held after sale: 218,406 shares +1 more

4 metrics

Shares sold 11,810 shares Open-market sale on 2026-04-01

Sale price $24.58 per share Price for Beam Therapeutics common stock sold

Shares held after sale 218,406 shares Direct holdings after the reported transaction

RSU grant vesting dates March 31, 2022, 2023, 2024, 2025 RSUs whose vesting triggered tax-withholding sale

Key Terms

restricted stock units, Rule 10b5-1 trading plan, tax withholding obligations, 2019 Equity Incentive Plan

4 terms

restricted stock units financial

"upon the vesting of certain restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding obligations financial

"sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations"

2019 Equity Incentive Plan financial

"under the Beam Therapeutics Inc. 2019 Equity Incentive Plan"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaramella Giuseppe

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		11,810	D	$24.58	218,406	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

	By: /s/ Christine Bellon, Attorney-in-fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beam Therapeutics (BEAM) report for its president?

Beam Therapeutics reported that President Giuseppe Ciaramella automatically sold 11,810 shares of common stock at $24.58 per share. The sale covered tax withholding obligations tied to vested restricted stock units under the company’s 2019 Equity Incentive Plan.

Why did Giuseppe Ciaramella’s Beam (BEAM) shares get sold in this Form 4 filing?

The shares were sold automatically to cover tax withholding obligations on vested restricted stock units. This was a non-discretionary transaction executed under a Rule 10b5-1 trading plan, rather than an active open-market decision to reduce his ownership stake.

How many Beam Therapeutics (BEAM) shares does the president hold after this Form 4?

After the reported transaction, President Giuseppe Ciaramella directly holds 218,406 shares of Beam Therapeutics common stock. This remaining position shows he continues to have a substantial equity stake in the company following the tax-related share sale.

What price was received for the Beam (BEAM) shares sold in this insider transaction?

The 11,810 Beam Therapeutics shares were sold at $24.58 per share. This price reflects the execution level for the automatic sale used to satisfy tax withholding obligations associated with previously granted restricted stock units that vested.

Was the Beam Therapeutics (BEAM) insider sale made under a Rule 10b5-1 plan?

Yes. The footnote states the tax-related sales were effected under a Rule 10b5-1 trading plan adopted on May 23, 2023. Such pre-arranged plans are designed to systematize trades and reduce the influence of inside information on transaction timing.